Business Wire

Galderma Campaign “Proof in Real Life”: Patients Tell their Stories One Year Later


In 2015, Sharon Stone, signed on to the “Proof in Real Life” campaign to help Galderma challenge common misconceptions of aesthetic treatments.

This Smart News Release features multimedia. View the full release here:

(Photo: Business Wire)

(Photo: Business Wire)

Galderma & Sharon Stone unveiled the natural-looking results of Restylane fillers and Restylane Skinboosters in a unique real-life format in Berlin, Germany. The Galderma Proof in Real Life campaign launch event saw ten pairs of identical twins take part in a unique challenge. One twin from each pair received a bespoke treatment plan which consisted of treatments with Restylane fillers, Restylane Skinboosters, or a combination of both. Twelve months on from the original campaign, both twins have now been treated.

Galderma met with them and asked them about their expectations, the results and their feelings, having all received the treatment.

Valuable Insights from the Twins and Aesthetic Professionals

To document their reactions, Galderma has launched a new film containing interviews with a number of the twins as well as insights from leading industry experts, featuring Plastic Surgeons, Dermatologists and Aesthetic Physicians.

It was quite an amazing journey for all of us, to be honest”, said Dr. Kuldeep Minocha, the aesthetic practitioner based in London, UK, who performed the treatments. “What was interesting is that all bar one of the sets of twins were treatment naïve. So, they hadn’t had any kind of injectables before. This was a very new step for them.

“So we took a lot of time in understanding what they felt about their skin and skin ageing. We educated them a little bit about the use of injectables, and talked to them about the various properties of what we could do with fillers to try and improve their skin but maintaining things as natural as possible. I think that was the biggest key, particularly when you’re treating patients who are naïve and who have not had any previous treatment and they don’t want too much change. So everything we want to do is to refresh the skin and make them look like the best versions of themselves.”

In the interview, Kelly, one of the twins treated in 2015, described the reactions.

“When I looked in the mirror after my treatments, I was really happy with the results. I was amazed how natural my skin looked, how natural my overall look was, so I was very pleased with what I saw, definitely. A lot of people said, ’You look really fresh, youthful, you’re glowing.’”

Agreement on the Importance of Natural Looking Results

One of the featured elements of the campaign was the focus on achieving natural- looking results. Dr. Van Park, a leading Cosmetic Physician from Sydney, Australia gave her views on patient expectations. “A natural looking result, to me, is undetectable. In my experience, when patients come and see me, they expect to become a better version of themselves. To look the best they can for as long as they can, rather than trying to look 20 years younger. They just want to look fresher and less tired.”

The interviewed professionals agree on this point. Dr. Marie-Thérèse Bousquet, who has worked with aesthetic medicine since 1992, says, “Natural beauty is essential for my patients and for me. They do not want their treatment to be seen.” She continues, “To achieve natural looking results, here is my way of working: I associate different treatments; I never over-correct; I am able to say “no” to the patient. My goal is an improvement of the face without being excessive.”

“Proof in Real Life” of Confidence and Self-Esteem

Another key focus area in the Proof In Real Life Campaign was learning about how patients felt about themselves after treatment.

“Patients often come to me saying they want something to make them look better, but the reality is that they’re asking for something to make them feel better,” says Dr. Steven Dayan, a facial Plastic Surgeon from Chicago, USA. “Perfection of beauty does not equal happiness. What we are actually trying to achieve is to make people feel better about themselves. That’s self-esteem.”

One of the twins, Amie, summed up her experience very eloquently: “I think the main thing people noticed in me after treatment was the confidence I had in myself.”

“The ‘Proof in Real Life’ Campaign has provided some remarkable insights into aesthetic treatments, how achievable and natural-looking these results can be,” said Anne-Sophie Copin, from Galderma. “It has highlighted the important positive effects that aesthetic treatment seem to have, not only on the outside, but also for patients’ confidence, well- being and self-esteem.”

Dr. Steven Dayan sees these kinds of results as central: “This all falls within the realm of what we do as Aesthetic Physicians.” Dr. Dayan concludes, “Restylane has been around for 20 years; it has been on the market in the U.S. since 2003. I’m very comfortable with Restylane and all its capabilities – we understand [Restylane] very well.

Experience for yourself how the twins reacted. Watch Galderma’s film “Proof in Real Life, Twelve Months On”:

About Galderma:

Dating back to 1961, Galderma is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care professionals around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin, hair and nails.

About Restylane:

Restylane is a range of Hyaluronic Acid (HA) dermal fillers for facial aesthetic treatments to efficiently reduce lines, folds and wrinkles, create fuller lips, enhance contours and facial volume, as well as improve skin quality, structure and elasticity. Restylane has an established safety profile based on over 2 decades of experience and extensive clinical documentation.

Today, with over 28 million treatments worldwide, Restylane is known for natural-looking results with long-lasting effects and high patient satisfaction. The Restylane range is designed to complement the varying stages of facial aging for truly individualized treatments that suit all patient needs.

Within the Restylane range there are two main product ranges:

  • Restylane fillers, designed to enhance and restore facial features, from targeted superficial filling of wrinkles to deeper facial shaping and contouring.
  • Restylane Skinboosters, a progressive approach to improved skin condition, designed to restore the skin’s hydrobalance and refresh the appearance.


“Proof in Real Life”, Twelve Months On:

Galderma Launches “Proof in Real Life”:

Legal Disclaimer:
As for all injection treatments using hyaluronic acid dermal fillers, side effects may occur in association with treatment. These side effects are usually mild to moderate, and include transient reactions such as redness, pain, swelling, bruising and/or bumps at the injection sites. Please consult your physician for additional information.
The reactions mentioned in this release are based on the individual’s own experiences and opinions and may not be what others will experience.
“Proof in Real Life” is not being activated in the US.
Restylane, Restylane Skinboosters and Galderma are trademarks of Nestlé Skin Health S.A.

© Nestlé Skin Health S.A. June 2016

Contact information

Mårten Forrest
Head of PR & Communication
Aesthetic & Corrective Business
Mobile: +46 768 98 1106

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on